drugset / Trial / NCT01579279

A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain

NCT01579279

Phase 2 Terminated 1 enrolled AbbVie
RandomizedParallel-groupTriple-blindTreatment

Summary

To evaluate the safety and efficacy of ABT-652 compared to Placebo in subjects with diabetic neuropathic pain. People with diabetes can, over time develop nerve damage throughout the body with symptoms such as pain, tingling, or numbness (loss of feeling) in the hands, arms, feet and legs.

Timeline

Start
2012-04
Primary completion
2012-05
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject ABT-652 Unknown 6 mg
Subject ABT-652 Unknown 12 mg
Subject ABT-652 Unknown 18 mg
Comparator Duloxetine Small molecule

Indications